The Latest Cardiac and Vascular News
LONDON–(BUSINESS WIRE)–LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full-year ended December 31, 2020. For the fourth quarter of 2020, worldwide sales from continuing operations were $269.6 million, a decrease of 6.3 percent on a reported basis and a decline […]
Wearable cardiac monitoring solution enables early detection and treatment of arrhythmia based on risk factors, according to results of the SCREEN-AF study published in JAMA Cardiology LONDON–(BUSINESS WIRE)–iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, today announced the results of a brand […]
SCHAFFHAUSEN, Switzerland, Feb. 24, 2021 /PRNewswire/ — Occlutech, a privately-held company, announced today the completion of patient enrolment in its pilot study to assess safety and efficacy of the novel Atrial Flow Regulator (AFR) in heart failure (HF) patients (PRELIEVE trial). PRELIEVE is a prospective, multicenter, open-label, non-randomized pilot study that evaluates the […]
– Transaction furthers Terumo’s efforts to improve patient outcomes and decrease healthcare costs through personalized predictive analytics and clinical decision support at the point of care – TOKYO, Feb. 23, 2021 /PRNewswire/ — Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all […]
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 /PRNewswire/ — United Therapeutics Corporation (Nasdaq: UTHR) today announced its financial results for the fourth quarter and year ended December 31, 2020. Full year net revenue rose to $1,483 million, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the […]
Intramyocardial injection of Lomecel-B well-tolerated, with no major cardiac events, and no serious adverse events related to Lomecel-B reported Full results of the Phase 1 clinical trial expected to be released in Q2 2021 Phase 2 trial expected to commence in Q3 2021 MIAMI, Feb. 24, 2021 (GLOBE NEWSWIRE) — […]
TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct […]
Fourth Quarter 2020 U.S. Product Revenue of $8.2 Million, Approximately 150 Percent Increase Compared to the Third Quarter Over 21,000 Patients on NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Tablets in the U.S. CLEAR Outcomes Study Design Highlighted in The American Heart Journal and Progresses Uninterrupted Despite Pandemic […]
– Significant pipeline progress with potentially first- or best-in-class drug candidates – Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO–(BUSINESS WIRE)–Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2020. “This […]
VANCOUVER, British Columbia–(BUSINESS WIRE)–Evasc Neurovascular is proud to announce its successful application to France’s Ministry of Health (Haute Autorité de la Santé, HAS) Forfait Innovation (FI) program for the eCLIPs™ device, published in its official journal December 23, 2020 – https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000042722732. The Forfait Innovation program grants clinical trial funding to evaluate […]
